News

Dec 4, 2024Antag Therapeutics Announces €80 Million Series A Financing
Sep 12, 2024Oruka Therapeutics Announces $200 Million Private Placement
Aug 9, 2024ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Jul 24, 2024Dren Bio announces strategic collaboration with Novartis to develop novel targeted myeloid engagers for cancer

12/04/2024Antag Therapeutics Announces €80 Million Series A Financing
11/20/2024Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
11/18/2024Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing
11/14/2024Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
11/09/2024ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
10/08/2024Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
10/01/2024Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director
09/12/2024Oruka Therapeutics Announces $200 Million Private Placement
09/12/2024Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
08/26/2024EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
08/12/2024Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
08/12/2024FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer
08/09/2024ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
08/06/2024Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
07/30/2024ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
07/24/2024Dren Bio announces strategic collaboration with Novartis to develop novel targeted myeloid engagers for cancer
07/18/2024Rezo Therapeutics Appoints Cristiana Guiducci, Ph.D., as Chief Scientific Officer
07/16/2024Nkarta announces leadership updates, appoints Nadir Mahmood as President
07/16/2024Asceneuron secures $100M Series C Financing to advance groundbreaking therapeutics in neurodegenerative diseases
07/08/2024Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
07/01/2024Zenas BioPharma appoints Orlando Oliveira as Chief Commercial Officer
06/28/2024ARS Pharmaceuticals announces EURneffy (adrenaline nasal spray) recommended for approval by CHMP for emergency treatment of allergic reactions (anaphylaxis
06/27/2024Nkarta initiates clinical trial of NKX019 in lupus nephritis with first patient in screening and announces pipeline expansion to additional autoimmune indications
06/27/2024Alumis announces pricing of initial public offering
06/14/2024Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
06/13/2024Nkarta adds experienced leader in autoimmune R&D, George Vratsanos, M.D., FACR, to board of directors
05/23/2024CRISPR Therapeutics strengthens executive leadership team with key appointments
05/20/2024Avalyn presents clinical data on AP01 for pulmonary fibrosis, including long- term efficacy and imaging biomarker data, at ATS 2024
05/09/2024Arcellx and Kite continue momentum with advances in anito-cel multiple myeloma program
05/07/2024Zenas BioPharma announces upsized $200M Series C Financing to advance mid- and late- stage immunology- focused clinical development programs
05/01/2024Avalyn bolsters leadership team with the appointment of Douglas Carlson as CFO and CBO
04/30/2024Alumis announces first participant dosed in Ph1 clinical trial of CNS penetrant allosteric TYK2 inhibitor A-005
04/15/2024Pulmocide announces successful results from the OPERA-S Study: a Ph2 safety study with inhaled opelconazole
04/04/2024Odyssey Therapeutics announces strategic collaboration to advance AI- driven small molecule drug discovery
04/03/2024ARS Pharma submits response to FDA complete response letter for neffy® (epinephrine nasal spray)
04/02/2024Odyssey Therapeutics Appoints Julie Clauss as Chief Operating Officer and Christopher Butler as SVP, Head of Chemistry
04/02/2024ADARx Pharmaceuticals appoints Dr. Chris Storgard as Chief Medical Officer
03/26/2024Avenzo Therapeutics announces $150M oversubscribed financing to advance emerging oncology pipeline
03/25/2024Nkarta announces pricing of $240M underwritten offering
03/13/2024CRISPR Therapeutics proposes new appointment to the board of directors
03/12/2024Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
03/09/2024Alumis presents positive data from Ph2 clinical trial of ESK-001, an oral allosteric TYK2 inhibitor for the treatment of plaque psoriasis at AAD Annual Meeting
03/06/2024Asceneuron expands scientific advisory board with world leading experts in neurodegenerative diseases
03/06/2024Alumis announces upsized $259M Series C financing to advance clinical- stage pipeline of oral therapies designed to address immune dysfunction
02/29/2024FORE Biotherapeutics names William R. Hinshaw as CEO
02/20/2024ARS Pharma announces favorable topline results from repeat dosing study of neffy® (Epinephrine Nasal Spray) under nasal allergen challenge conditions, readies data for response to FDA's complete response letter
02/13/2024CRISPR Therapeutics announces $280M registered direct offering
02/08/2024Renalys Pharma Is Launched To Bring New Innovative Medicines To Patients In Japan and Other Countries In Asia
01/08/2024Simcha Therapeutics announces license & option agreement to develop novel decoy- resistant IL-18 for use in cell therapy applications
01/04/2024Avenzo Therapeutics announces global license of AVZO-021 (ARTS-021), a potentially best- in- class clinical stage CDK2 inhibitor from Allorion Therapeutics
12/08/2023CRISPR Therapeutics and Vertex announce US FDA approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
12/05/2023Odyssey Therapeutics announces $101M Series C
11/16/2023CRISPR Therapeutics and Vertex announce authorization of the first CRISPR/Cas9 Gene- Edited Therapy, CASGEVY™, by the UK MHRA
11/15/2023US FDA approves Bristol- Myers Squibb's (BMY.N) lung cancer drug that was acquired as part of the company's $4.1B buyout of Turning Point Therapeutics (TPTX)
11/15/2023Arcellx and Kite announce expansion in strategic partnership
10/30/2023Dren Bio appoints Amit Mehta as Chief Operating Officer and Chief Business Officer
09/27/2023Avalyn Raises $175M in oversubscribed Series C financing to advance inhaled pulmonary fibrosis programs into later stage clinical studies
09/20/2023Rezo Therapeutics appoints Nadir Mahmood as CEO
09/06/2023Nimbus Therapeutics secures $210M in private financing
08/23/2023FORE Biotherapeutics announces $75M in Series D and CEO Transition
08/09/2023ADARx Pharmaceuticals announces oversubscribed $200M Series C
07/06/2023Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)
07/05/2023Nkarta appoints Alyssa Levin CBO and CFO
06/08/2023FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia
04/11/2023HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B
04/05/2023Simcha Therapeutics announces clinical trial collaboration with Merck to evaluate ST-067 in combination with KEYTRUDA® (Pembrolizumab)
03/27/2023SR One Closes Second Venture Fund at $600M
02/14/2023Mineralys Therapeutics prices $221M IPO
01/20/2023ADARx Pharmaceuticals raises $46M in Series B-1 and appoints Dr. Lorence Kim to Board of Directors
01/09/2023ADARx Pharmaceuticals appoints Robert MacLeod as CSO
01/05/2023Akamis Bio raises $30M financing and relaunches with name change from PsiOxus Therapeutics
01/03/2023HotSpot Therapeutics announces FDA clearance of IND application for HST-1011, an investigational small molecule allosteric inhibitor of CBL-B
12/13/2022Nimbus Therapeutics TYK2 program to be acquired by Takeda for $4B in upfront cash and up to $2B in potential commercial milestone payments
12/09/2022Arcellx announces strategic collaboration with Kite, a Gilead Company, to co-develop and co- commercialize late- stage clinical CART-ddBCMA in multiple myeloma
12/06/2022HotSpot Therapeutics launches strategic collaboration with AbbVie to further expand immunology pipeline
11/30/2022Nimbus Therapeutics announces positive topline results for Ph2b clinical trial of allosteric TYK2 inhibitor
11/17/2022Rezo Therapeutics, founded by renowned UCSF scientists, raises $78M in Series A
11/08/2022ARS Pharmaceuticals closes merger with Silverback Therapeutics and currently has over $280M in cash
10/26/2022Nimbus Therapeutics appoints Nathalie Franchimont as CMO
10/13/2022Odyssey Therapeutics raises $168M in Series B
10/11/2022Nimbus Therapeutics announces research collaboration and license agreement with Lilly
09/28/2022ADARx Pharmaceuticals appoints Christopher Prentiss as CFO
09/12/2022Nimbus Therapeutics closes $125M in private financing
08/16/2022Simcha Therapeutics accelerates growth with key leadership appointments, expanded research and option agreement with Yale School of Medicine
08/11/2022PsiOxus Therapetuics appoints Howard Davis as CEO
08/04/2022MiroBio to be acquired by Gilead Sciences for $405M
07/25/2022HotSpot Therapeutics appoints Paul Thibodeau as CBO
07/21/2022ARS Pharmaceuticals and Silverback Therapeutics announces merger
07/19/2022HotSpot Therapeutics appoints Jose Carmona to Board of Directors
07/05/2022Ancora Biotech lead clinical asset, TeneoTwo, to be acquired by AstraZeneca for up to $1.27B
06/29/2022MiroBio raises $97M in Series B
06/21/2022Arcellx appoints Maryam Abdul-Kareem as General Counsel
06/21/2022Arcellx raises $128M in follow-on financing
06/14/2022Dren Bio raises $65M in Series B
06/11/2022CRISPR Therapeutics presents positive results from its Ph1 COBALT™-LYM trial of CTX130™ in relapsed or refractory T cell malignancies
06/11/2022CRISPR Therapeutics and Vertex presents new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel)
06/09/2022Ancora Biotech raises $60M in Series A
06/08/2022Mineralys Therapeutics raises $118M in Series B
06/05/2022eFFECTOR Therapeutics reports positive interim results in zotatifin (EFT226) Ph1/2 clinical trial
06/03/2022Turning Point Therapeutics to be acquired by Bristol Myers Squibb for $4.1B
06/03/2022Arcellx presents continued robust long-term responses from its CART-DdBCMA Ph1 expansion trial
05/24/2022Odyssey Therapeutics appoints Darryl Patrick as Executive Vice President of Non-Clinical Development
05/23/2022Arcellx appoints Michelle Gilson as CFO
05/19/2022Odyssey Therapeutics appoints Jeffrey M. Leiden as Board Chair
05/16/2022CRISPR Therapeutics appoints Phuong Khanh Morrow as CMO
05/16/2022Arcellx appoints Olivia Ware to Board of Directors
05/10/2022Arcellx announces dosing of first patient in its Ph1 clinical trial evaluating ACLX- 001, the first therapeutic in the dosable and controllable ARC- SparX Platform
04/28/2022Nkarta Therapeutics raises $230M in follow-on financing
04/25/2022BioTheryX appoints Jeff Caravella as CFO
04/25/2022Nkarta Therapeutics announces positive preliminary dose finding data for two lead engineered natural killer cell programs
04/12/2022CRISPR Therapeutics appoints Maria Fardis to Board of Directors
04/05/2022ARS Pharmaceuticals appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as CFO
03/25/2022Nimbus Therapeutics presents clinical data from Ph1 study of oral allosteric TYK2 inhibitor at AAD Annual Meeting
03/08/2022MiroBio continues expansion of executive leadership team
02/23/2022BioTheryX appoints Nancy Miller- Rich as Board Chair
02/16/2022eFFECTOR Therapeutics appoints Kristen Harrington-Smith to Board of Directors
02/10/2022Second Genome nominates development candidate targeting PAI-1/2 for the treatment of inflammatory bowel disease
02/09/2022ARS Pharmaceuticals expands executive leadership team
02/09/2022Decibel Therapeutics reports on continued progress of lead gene therapy product candidate DB-OTO
02/08/2022Arcellx prices $142.3M IPO
02/02/2022CRISPR Therapeutics and ViaCyte announce first patient dosed in Ph1 clinical trial
02/02/2022Nimbus Therapeutics shares update on discovery efforts in computational chemistry and expands leadership team
02/01/2022Design Therapeutics appoints Jae Kim as CMO
01/27/2022Simcha Therapeutics raises $40M in Series B
01/26/2022BioTheryX doses first patient in Ph1 study investigating lead protein degrader candidate BTX-1188
01/25/2022ADARx Pharmaceuticals expands leadership team
01/20/2022BioTheryX appoints Sahm Nasseri as CBO
01/20/2022Palleon Pharmaceuticals announces IND clearance for its lead candidate E-602
01/20/2022Turning Point Therapeutics announces FDA clearance of IND application for combination of Elzovantinib and Aumolertinib in EGFR mutant MET-amplified non-small cell lung cancer
01/19/2022Second Genome appoints Joseph Dal Porto as CSO
01/11/2022Dren Bio announces research collaboration and license agreement with Pfizer
01/10/2022HotSpot Therapeutics and Caris Life Sciences announce collaboration
01/06/2022Odyssey Therapeutics acquires Rahko
01/06/2022Nimbus Therapeutics announces expansion of oral allosteric TYK2 inhibitor program
01/05/2022Bicycle Therapeutics announces continued clinical progress and updates to management team
01/05/2022ADARx Pharmaceuticals appoints Dr. Hubert Chen as CMO
12/20/2021Second Genome granted U.S. patent for proteins for the treatment or prevention of epithelial barrier function disorders
12/16/2021Nkarta receives U.S. FDA orphan drug designation for NKX101 for treatment of patients with AML
12/16/2021Palleon Pharmaceuticals appoints Denis Patrick to its Board of Directors
12/13/2021Arcellx presents continued robust long-term responses from its CART-ddBCMA Ph1 expansion trial
12/08/2021Nomic Bio raises $17M in Series A
12/08/2021Tranquis Therapeutics announces initiation of Ph1 study of TQS-168
12/07/2021Odyssey Therapeutics raises $218M in Series A
12/06/2021Pulmocide receives $3.5M investment from the Cystic Fibrosis Foundation
11/29/2021HotSpot Therapeutics raises $100M in Series C
11/22/2021CRISPR Therapeutics announces FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted to CTX110™
11/09/2021Palleon presents data on sialoglycan degradation platform that enhances anti-tumor T-cell immunity
11/03/2021Tranquis Therapeutics presents positive preclinical data on TQS-168 for the treatment of ALS
11/02/2021Palleon Pharmaceuticals appoints David Johnson to its Board of Directors
11/02/2021BioTheryX receives IND clearance from FDA to proceed with Ph1 Study of BTX-1188
10/28/2021BioTheryX appoints Philippe Drouet as CEO
10/18/2021Bicycle Therapeutics raises $201.3M
10/12/2021CRISPR Therapeutics reports positive results from its Ph1 CARBON Trial of CTX110™
10/07/2021Bicycle Therapeutics announces preliminary results from Ph1 oncology trials
10/04/2021Turning Point Therapeutics granted breakthrough therapy designation for Repotrectinib treatment
09/21/2021MiroBio appoints Dr. Carolin Barth as CEO
09/15/2021PsiOxus Therapeutics to present positive biomarker data at ESMO 2021
09/08/2021ADARx Pharmaceuticals raises $75M in Series B
08/31/2021ARS Pharmaceuticals raises $55M in Series D
08/25/2021eFFECTOR Therapeutics debuts as public company
08/16/2021Turning Point Therapeutics initiates Ph1b/2 combination study
08/06/2021BioTheryX appoints three new members to its Board of Directors
08/04/2021eFFECTOR Therapeutics initiates Zotatifin Ph2a in breast and lung cancers
07/22/2021eFFECTOR Therapeutics doses first COVID- 19 patient in Zotatifin Ph1b trial
07/13/2021Nimbus Therapeutics raises $105M from top investors
07/13/2021Bicycle Therapeutics enters exclusive license and collaboration agreement with Ionis
07/09/2021Morphic Therapeutic new data from positive Ph1 study of MORF-057
06/17/2021Turning Point Therapeutics receives orphan drug designation for TPX-0022 in gastric cancer
06/15/2021CRISPR Therapeutics and Capsida Biotherapeutics announce strategic collaboration
06/09/2021eFFECTOR Therapeutics doses first patient in Ph2b kickstart clinical trial
05/27/2021Pulmocide raises $92M in Series C
05/27/2021eFFECTOR Therapeutics and Locust Walk Acquisition Corp Annouce Merger
05/26/2021Tranquis Therapeutics appoints Frederic Godderis as COO and Jonas Hannestad as CMO
05/25/2021Turning Point Therapeutics appoints Mark Alles to chair its Board of Directors
05/20/2021BioTheryX raises $92M in Series E
05/19/2021Arcellx to present data at ASCO 2021
05/19/2021Fore Biotherapeutics strengthens leadership team
05/06/2021CRISPR Therapeutics and Nkarta announce global collaboration
05/04/2021eFFECTOR Therapeutics and UCSF receive $5M from DARPA for Covid study
04/20/2021CRISPR Therapeutics amends partnership with Vertex Pharmaceuticals
04/19/2021Arcellx appoints Dr. Christopher as CMO and Neeraj Teotia as CCO
04/14/2021PsiOxus Therapeutics and bluebird bio present preclinical data at AACR 2021
04/14/2021HotSpot Therapeutics appoints Timothy Reilly as Chief Development Officer
04/13/2021Arcellx raises $115M in Series C
04/10/2021Bicycle Therapeutics presents preclinical data at AACR 2021
04/01/2021Pandion Therapeutics acquired by Merck for $1.85BN
03/30/2021Design Therapeutics prices $276M IPO
03/18/2021Bicycle Therapeutics appoints Jose-Carlos Gutierrez-Ramos as Board Director
03/11/2021Positive clinical updates of PC945 in lung infections
03/01/2021Positive interim Phase 1 results of oral integrin therapy
02/22/2021Fore Biotherapeutics appoints Dieter Weinand as Board Chairman and Usama Malik as CEO and Board Director
02/22/2021Preclinical data supporting local immune modulation platform
02/11/2021SR One adds Venture Partners to deepen operational expertise
02/11/2021Decibel Therapeutics prices $127M IPO
01/27/2021Narrow River management raises $40M each for two new renal companies
01/27/2021Design Therapeutics raises $125M Series B
01/26/2021Arcellx appoints Rami Elghandour as Chairman and CEO
01/25/2021Second Genome appoints Dr. Susannah Cantrell as CBO and Dr. Preeti Gupta Lal as CSO
01/14/2021Clinical progress across oncology pipeline
01/07/2021eFFECTOR Therapeutics appoints Mike Byrnes as CFO
12/10/2020FDA accepts BLA for Reltecimod
12/08/2020Repotrectinib treatment in TKI naive patients granted FDA breakthrough therapy designation
12/07/2020Cell therapy demonstrates durable responses in multiple myeloma
12/05/2020Update on gene editing for sickle cell disease and beta-thalassemia
12/04/2020Palleon Pharmaceuticals appoints Deepa Pakianathan as Board Director
12/04/2020Morphic Therapeutic appoints Dr. Martin W. Edwards as Board Director
12/03/2020Pandion Therapeutics appoints Katina Dorton as Board Director
11/19/2020SR One Raises $500M; Completes Spinout from GSK
11/17/2020HotSpot Therapeutics appoints Eva Jack as COO
11/09/2020Decibel Therapeutics raises $82M Series D
11/02/2020Mission Therapeutics appoints Dr. Suhail Nurbhai as CMO
10/26/2020Turning Point Therapeutics raises $400M
10/21/2020Early response data with gene edited cell therapy for B-cell malignancies
10/20/2020Nobel Prize in chemistry awarded to CRISPR Therapeutics founder Emmanuelle Charpentier
10/20/2020Design Therapeutics appoints Joao Siffert as CEO
10/16/2020Dren Bio raises $60M Series A
10/15/2020eFFECTOR Therapeutics appoints Premal Patel as CMO
10/14/2020Nimbus Therapeutics raises $60M
10/05/2020Nkarta Therapeutics appoints Nadir Mahmood as CFO/CBO and Alicia J. Hager as Chief Legal Officer
09/21/2020Fore Biotherapeutics raises $57M Series C
09/17/2020Palleon Pharmaceuticals raises $100M Series B
08/19/2020Early interim data from Trident-1, a registrational Phase 2 of Repotrectinib
08/17/2020Principia Biopharma acquired by Sanofi for $3.7BN
07/16/2020Pandion Therapeutics prices $135M IPO
07/10/2020Nkarta Therapeutics prices $290M IPO
07/09/2020Tranquis Therapeutics raises $30M Series A
07/06/2020Mission Therapeutics raises $15M
06/30/2020CRISPR Therapeutics raises $450M
05/29/2020Tomivosertib demonstrates positive Phase 2 results in combination with checkpoint inhibitors for NSCLC patients
05/21/2020HotSpot Therapeutics raises $65M Series B
05/19/2020Pandion Therapeutics appoints John Sundy as CMO
04/06/2020Second Genome and Gilead Sciences announce strategic collaboration
04/01/2020Pandion Therapeutics raises $80M Series B
03/20/2020Design Therapeutics raises $45M Series A
03/05/2020PsiOxus Therapeutics appoints Dr. Tom Lillie as CMO
01/20/2020FDA approves TEPEZZA™ for the treatment of Thyroid Eye Disease